BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacious in adults ≥50 years of age. We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule, by following up adults vaccinated at ≥60 years of age and by modeling, and (2) immunogenicity of 2 additional doses administered 10 years after initial vaccination. METHODS: Persistence of humoral and cell-mediated immune (CMI) responses to 2 initial RZV doses was assessed through 10 years after initial vaccination, and modeled through 20 years using a Piecewise, Power law and Fraser model. The immunogenicity and safety of 2 additional RZV doses were also evaluated. RESULTS: Seventy adults were enrolled. Ten years after initial vaccination, humoral and CMI responses were approximately 6-fold and 3.5-fold, respectively, above those before the initial vaccination levels. Predicted immune persistence through 20 years after initial vaccination was similar across the 3 models. Sixty-two participants (mean age [standard deviation], 82.6 [4.4] years) received ≥1 additional RZV dose. Strong anamnestic humoral and CMI responses were elicited by 1 additional dose, without further increases after a second additional dose. CONCLUSIONS: Immune responses to an initial 2-dose RZV course persisted for many years in older adults. Strong anamnestic immune responses can be induced by additional dosing 10 years after the initial 2-dose course. CLINICAL TRIALS REGISTRATION: NCT02735915.

Centre for Clinical Research Eskilstuna Sweden

Department of Infectious Diseases Uppsala University Hospital Uppsala Sweden

Faculty of Military Health Sciences University of Defence Hradec Kralove Czech Republic

GSK Rixensart Belgium

GSK Rockville Maryland USA

GSK Wavre Belgium

Klinikum Wuerzburg Mitte Standort Juliusspital Wuerzburg Germany

Mithra Pharmaceuticals Flémalle Belgium

UCB Pharma Braine L'Alleud Belgium

Uppsala University Sweden

Zobrazit více v PubMed

Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology 2013; 81:928–30. PubMed PMC

Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc 2017; 92:1806–21. PubMed

Lal H, Cunningham AL, Godeaux O, et al. ; ZOE-50 Study Group . Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087–96. PubMed

Cunningham AL, Lal H, Kovac M, et al. ; ZOE-70 Study Group . Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375:1019–32. PubMed

Cunningham AL, Heineman TC, Lal H, et al. ; ZOE-50/70 Study Group . Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis 2018; 217:1750–60. PubMed PMC

Chlibek R, Smetana J, Pauksens K, et al. . Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 2014; 32:1745–53. PubMed

Chlibek R, Pauksens K, Rombo L, et al. . Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 2016; 34:863–8. PubMed

Schwarz TF, Volpe S, Catteau G, et al. . Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 2018; 14:1370–7. PubMed PMC

Lal H, Chlibek R, Pauksens K, et al. . Persistence of the immune response to an adjuvanted herpes zoster subunit vaccine in healthy older adults: modeling of vaccine-induced immune response, data from a 6-year follow-up study. Open Forum Infect Dis 2015; 2:1931.

David MP, Van Herck K, Hardt K, et al. . Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009; 115:S1–6. PubMed

Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342:341–57. PubMed

López-Fauqued M, Campora L, Delannois F, et al. ; ZOE-50/70 Study Group . Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine 2019; 37:2482–93. PubMed

Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02735915